Genetic Matching Hypotheses, GLP-1GIPLani
This allows the clinical team to screen for any potential issues before you begin
however, the incidence of acute gallbladder disease was greater in Saxenda -treated patients than in placebo-treated patients even after accounting for the degree of weight loss
Patients may consider microdosing if they: Have a small amount of weight to lose Want help reducing food noise Are interested in weight maintenance Are sensitive to medication side effects Want a gradual introduction to GLP-1 therapy Flow Wellness works with patients to determine whether a lower-dose approach aligns with their goals
In the STEP 1 trial (New England Journal of Medicine, 2021), adults with overweight or obesity without diabetes lost about 15 percent of their body weight over 68 weeks on semaglutide 2.4 mg, compared with roughly 2 to 3 percent in the placebo group, when all participants received lifestyle counseling
This is distinct from the appetite-suppressing effect of GLP-1 and GIP
